These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 16424644)

  • 21. Autologous stem cell transplantation in first-line treatment of high-risk aggressive non-Hodgkin's lymphoma.
    Vranovsky A; Ladicka M; Lakota J
    Neoplasma; 2008; 55(2):107-12. PubMed ID: 18652043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [High-dose chemotherapy with autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in complete response as consolidation therapy, second report].
    Yamane T; Hirose A; Nakajima Y; Nakane T; Koh H; Takeoka Y; Nakamae M; Yamamura R; Nakamae H; Nakao Y; Mugitani A; Yagi T; Teshima H; Hino M
    Gan To Kagaku Ryoho; 2006 Feb; 33(2):193-8. PubMed ID: 16484855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.
    Moreau P; Milpied N; Voillat L; Colombat P; Mahé B; Rapp MJ; Moreau A; Dupas B; Bulabois CE; Juge-Morineau N; Harousseau JL
    Bone Marrow Transplant; 1998 Jun; 21(12):1193-6. PubMed ID: 9674850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
    Rodriguez J; Caballero MD; Gutierrez A; Gandarillas M; Sierra J; Lopez-Guillermo A; Sureda A; Zuazu J; Marin J; Arranz R; Carreras E; Leon A; De Sevilla AF; San Miguel JF; Conde E;
    Haematologica; 2003 Dec; 88(12):1372-7. PubMed ID: 14687990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [High-dose therapy and peripheral blood stem cell transplantation for patients with aggressive non-Hodgkin's lymphoma remaining in initial remission: results of a feasibility study].
    Kitajima H; Nasu K; Tsudo M; Fujimoto M; Hayashi K; Ohno H; Konaka Y; Katsurada T; Arima N; Doi S; Moriguchi T; Fukuhara S
    Rinsho Ketsueki; 2001 Mar; 42(3):191-8. PubMed ID: 11345781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy.
    Federico M; Bellei M; Brice P; Brugiatelli M; Nagler A; Gisselbrecht C; Moretti L; Colombat P; Luminari S; Fabbiano F; Di Renzo N; Goldstone A; Carella AM;
    J Clin Oncol; 2003 Jun; 21(12):2320-5. PubMed ID: 12805333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
    Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
    Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.
    Milpied N; Deconinck E; Gaillard F; Delwail V; Foussard C; Berthou C; Gressin R; Lucas V; Colombat P; Harousseau JL;
    N Engl J Med; 2004 Mar; 350(13):1287-95. PubMed ID: 15044639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte.
    Mounier N; Gisselbrecht C; Brière J; Haioun C; Feugier P; Offner F; Recher C; Stamatoullas A; Morschhauser F; Macro M; Thieblemont C; Sonet A; Fabiani B; Reyes F;
    J Clin Oncol; 2004 Jul; 22(14):2826-34. PubMed ID: 15254050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
    Rigacci L; Carrai V; Nassi L; Alterini R; Longo G; Bernardi F; Bosi A
    Cancer; 2005 Mar; 103(5):970-7. PubMed ID: 15666323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
    Colombat P; Cornillet P; Deconinck E; Tourani JM; Gardembas M; Delain M; Abgrall JF; Kootz C; Milpied N
    Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index.
    Bertz H; Zeiser R; Lange W; Fetscher S; Waller CF; Finke J
    Ann Oncol; 2004 Sep; 15(9):1419-24. PubMed ID: 15319249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study.
    Kluin-Nelemans HC; Zagonel V; Anastasopoulou A; Bron D; Roozendaal KJ; Noordijk EM; Musson H; Teodorovic I; Maes B; Carbone A; Carde P; Thomas J
    J Natl Cancer Inst; 2001 Jan; 93(1):22-30. PubMed ID: 11136838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial.
    Schouten HC; Qian W; Kvaloy S; Porcellini A; Hagberg H; Johnsen HE; Doorduijn JK; Sydes MR; Kvalheim G
    J Clin Oncol; 2003 Nov; 21(21):3918-27. PubMed ID: 14517188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma.
    Kaiser U; Uebelacker I; Abel U; Birkmann J; Trümper L; Schmalenberg H; Karakas T; Metzner B; Hossfeld DK; Bischoff HG; Franke A; Reiser M; Müller P; Mantovani L; Grundeis M; Rothmann F; von Seydewitz CU; Mesters RM; Steinhauer EU; Krahl D; Schumacher K; Kneba M; Baudis M; Schmitz N; Pfab R; Köppler H; Parwaresch R; Pfreundschuh M; Havemann K
    J Clin Oncol; 2002 Nov; 20(22):4413-9. PubMed ID: 12431962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).
    Schmitz N; Nickelsen M; Ziepert M; Haenel M; Borchmann P; Schmidt C; Viardot A; Bentz M; Peter N; Ehninger G; Doelken G; Ruebe C; Truemper L; Rosenwald A; Pfreundschuh M; Loeffler M; Glass B;
    Lancet Oncol; 2012 Dec; 13(12):1250-9. PubMed ID: 23168367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.